Is muscarinic receptor agonist effective and tolerant for schizophrenia?
Abstract Background Several randomized clinical trials (RCTs) have recently examined the efficacy and tolerability of muscarinic receptor agonists in schizophrenia. However, whether therapeutics targeting muscarinic receptors improve symptom management and reduce side effects remains systemically un...
Saved in:
| Main Authors: | Xiaonan Guo, Rongshan Deng, Jianbo Lai, Shaohua Hu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-025-06662-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia
by: Brian Dean
Published: (2024-12-01) -
Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials
by: Hazem E. Mohammed, et al.
Published: (2025-03-01) -
Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review
by: Michał Mazur, et al.
Published: (2025-04-01) -
Treatment Of Schizophrenia With Cobenfy (KarXT): A Literature Review
by: Laura Kurczoba, et al.
Published: (2025-05-01) -
Early outpatient clinical experience with xanomeline and trospium chloride for schizophrenia: a case report
by: Maxwell Zachary Price, et al.
Published: (2025-06-01)